Should surgeons reconsider the role of intraoperative sentinel lymph node evaluation for premenopausal breast cancer patients in the era of RxPONDER?

Tremendous improvements in the role of personalized breast cancer care have resulted in paradigms shifts to treatment algorithms, particularly regarding the role of systemic chemotherapy in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The landmark TAILORx data demonstrated the utility and efficacy of the 21-gene recurrence score assay (Oncotype DX, Genomic Health) in women with HR-positive, HER2-negative, node-negative breast cancer as it demonstrated a statistically and clinically significant benefit to the receipt of adjuvant chemoendocrine therapy vs endocrine therapy alone for patients with a recurrence score>25.
Source: American Journal of Surgery - Category: Surgery Authors: Tags: My Thoughts / My Surgical Practice Source Type: research